



(51) International Patent Classification:

C07D 471/04 (2006.01) *A61P 35/00* (2006.01)
A61K 31/437 (2006.01)

(21) International Application Number:

PCT/GB2014/051607

(22) International Filing Date:

27 May 2014 (27.05.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/827,951 28 May 2013 (28.05.2013) US
61/915,685 13 December 2013 (13.12.2013) US

(71) Applicant (for all designated States except MG): **ASTRAZENECA AB** [SE/SE]; SE-151 85 Södertälje (SE).(71) Applicant (for MG only): **ASTRAZENECA UK LIMITED** [GB/GB]; 2 Kingdom Street, London Greater London W2 6BD (GB).

(72) Inventors: **AKHTAR, Nadim**; AstraZeneca, Charter Way, Macclesfield, Cheshire SK10 2NA (GB). **BRADBURY, Robert, Hugh**; AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **BUTTAR, David**; AstraZeneca, Charter Way, Macclesfield, Cheshire SK10 2NA (GB). **CURRIE, Gordon, Stuart**; AstraZeneca, Charter Way, Macclesfield, Cheshire SK10 2NA (GB). **DE SAVI, Christopher**; AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451 (US). **DONALD, Craig, Samuel**; AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **NORMAN, Richard, Albert**; AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **OSBORNE, Matthew**; As-

traZeneca, Charter Way, Macclesfield, Cheshire SK10 2NA (GB). **RABOW, Alfred, Arthur**; AstraZeneca R&D Alderley, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). **REDFEARN, Heather, Marie**; AstraZeneca, Charter Way, Macclesfield, Cheshire SK10 2NA (GB). **WILLIAMS, Helen, Elizabeth**; AstraZeneca, Charter Way, Macclesfield, Cheshire SK10 2NA (GB). **YAVARI, Neda**; AstraZeneca, Charter Way, Macclesfield, Cheshire SK10 2NA (GB).


(74) Agent: **WILLIAMS, Anne**; Alderley Park, AstraZeneca Intellectual Property, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: CHEMICAL COMPOUNDS



(57) Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R¹ to R⁵ have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.

WO 2014/191726 A1



Published:

— *with international search report (Art. 21(3))*